, former Deputy Director of the FDA’s Oncology Center of Excellence, has joined 

 as Vice President, Regulatory Consulting Services. The company also announced 

, as Senior Medical Director, Global Therapeutic Area Lead, Oncology/Hematology within PAREXEL’s Global Medical Services team. 

 as its new leader of its Quality Assurance Unit and will be responsible for all of Avomeen’s DEA, FDA and ISO 17025 compliant operations and facility.

 has made the following appointments: Juliet Moritz has been appointed as its Vice President, Patient and Stakeholder Engagement (PASE); 

 as executive director of clinical development services, medical device and diagnostics; and 

 has been named director of regulatory affairs, medical device, and business strategy.

 is the company’s new vice president and general manager for the SHYFT RWE solutions team. Additionally, 

will join the company as Chief People Officer.

 as Head of Marketing, bringing over a decade of eClinical technology marketing experience to the role.

, MSc, is now the Executive Vice President of Clinical Operations, based in their UK office.

	To kick off Rare Disease Day on February 28 and March as Rare Disease Month, 

 announced a new scholarship for rare disease patient advocates in partnership with Professional Patient Advocates in Life Sciences (PPALS).

 announced one of its Clinical Research Scientist 

 was recently honored by the Triangle Business Journal as a 2019 Health Care Hero. Vaughn was honored in the Volunteer category for her personal and professional dedication to advancing a cure for Cystic Fibrosis. 

 announced four of the world’s top seven largest CROs are standardizing on Veeva Vault eTMF. Vault eTMF  enables CROs to maintain an always up-to-date TMF and gives sponsors greater control of standard operating procedures for TMF management.

, a global, midsized CRO, marked its 25th anniversary with several announcements, including enhancing its rare disease services and elevating it to their Center of Excellence (COE) tier, thus joining oncology-hematology and infectious disease and vaccines in this category.

 recently closed its first full quarter as a combined business--after CRF Health and Bracket merged in September 2018--with a 20%-plus increase in new clinical trial business.

, a life sciences clinical and bioanalytical contract solutions provider, announced positive preliminary data from a controlled human infection trial with FluGen Inc.’s investigational M2SR vaccine that aimed to assess whether the vaccine could induce broadly protective immune responses and protect against the substantially mismatched SGS challenge strain. The study was carried out at the human challenge unit within SGS’s clinical pharmacology unit in Antwerp, Belgium.